Skip to main content
Signal8
Launch Terminal

ESTABLISHMENT LABS HOLDINGS INC. (ESTA)

Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.

Sector: Orthopedic, Prosthetic & Surgical Appliances & Supplies

Industry: Medical - Devices

Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

NASDAQ:ESTAHealthcare
-8.70%$62.46
AH$62.11-0.56%vs close
Mkt Cap$1.86B
Float24.1M
O/S29.8M
Vol
$ Vol
RVOL
Inst Own93.9%
SI16.7%
Earnings
Dilution
Establishment Labs Holdings Inc. logoNASDAQ:ESTA$62.46-8.70%
Phase Distribution
7 lead-sponsored trials·3 active·3 completed
Not applicable7
Status Overview
Recruiting3
Completed3
Unknown1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
  • Not applicable
    Unknown status

    Motiva Flora Tissue Expander PMCF

    Breast Tissue Expander

    Breast Tissue Accessory, Breast Cancer

    Enrollment
    136
    Start
    Dec 2020
    Primary Completion
    Dec 2024est.
    Completion
    Jul 2026est.
    NCT05447988
  • Observational
    Completed

    Retrospective Data Collection on the Use of Motiva Flora TE in Breast Reconstruction

    Motiva Flora TE

    Breast Cancer

    Enrollment
    144
    Start
    Sep 2022
    Primary Completion
    Jun 2024
    Completion
    Jun 2024
    NCT05459064
  • Not applicable
    Recruiting

    Motiva Flora® Aesthetic Breast Recon® Clinical Study

    Motiva Flora® Tissue Expander

    Mammaplasty, Breast Cancer +1

    Enrollment
    66
    Start
    Aug 2023
    Primary Completion
    Apr 2026est.
    Completion
    Apr 2027est.
    NCT06146231
  • Observational
    Completed

    Safety and Performance of Motiva® Sizers

    Motiva Sizer

    Breast Implant; Complications, Breast Implantation; Methods, Safety and Performance +3

    Enrollment
    133
    Start
    Apr 2023
    Primary Completion
    Dec 2023
    Completion
    Jan 2026
    NCT06274736
  • Not applicable
    Completed

    Mia® Clinical Study

    Minimally invasive breast augmentation procedure with a trans-axillary approach.

    Breast Augmentation

    Enrollment
    100
    Start
    Dec 2020
    Primary Completion
    Aug 2024
    Completion
    Dec 2024
    NCT06792409
  • Not applicable
    Recruiting

    Adaptive Study to Assess the Safety and Functioning of Motiva Devices on Minimally Invasive Gluteal Augmentation

    Primary gluteal enhancement

    Device Safety

    Enrollment
    120
    Start
    Apr 2023
    Primary Completion
    Apr 2026est.
    Completion
    Apr 2026est.
    NCT07135011
  • Observational
    Enrolling by invitation

    Clinical Study on Tissue Preservation in Breast Augmentation and Reconstruction

    Mia Harmonization, Mia Scarless Lift

    Breast Augmentation and Breast Reconstruction, Mammaplasty +2

    Enrollment
    60
    Start
    May 2025
    Primary Completion
    Dec 2026est.
    Completion
    Feb 2029est.
    NCT07623564
Search ClinicalTrials.gov for “Establishment Labs Holdings”